 |
|
Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions
Won-Il Choi
Precis Future Med. 2021;5(1):31-40. Published online 2021 Mar 2 DOI: https://doi.org/10.23838/pfm.2020.00205
|
|
Citations to this article as recorded by
 Ciplukan (Physalis angulata Linn) Bioactivity against Bleomycin-Induced Pulmonary Fibrosis in Mice by reducing Subpleural Fibrosis, KL-6 Level and Anti-Inflammatory properties
Sumartini Dewi, Enny Rohmawaty, Aziiz Mardanarian Rosdianto, Hermin Aminah Usman, Ade Zuhrotun, Rini Hendriani, Yoga Windhu Wardhana, Savira Ekawardhani, Hesti Lina Wiraswati, Iceu Dimas Kulsum, Andri Reza Rahmadi, Emmy H. Pranggono
Research Journal of Pharmacy and Technology.2024; : 1731. CrossRef Pirfenidone Inhibits Alveolar Bone Loss in Ligature-Induced Periodontitis by Suppressing the NF-κB Signaling Pathway in Mice
Zijiao Zhang, Juhan Song, Seung-Hee Kwon, Zhao Wang, Suk-Gyun Park, Xianyu Piao, Je-Hwang Ryu, Nacksung Kim, Ok-Su Kim, Sun-Hun Kim, Jeong-Tae Koh
International Journal of Molecular Sciences.2023; 24(10): 8682. CrossRef Inhaled pulmonary surfactant biomimetic liposomes for reversing idiopathic pulmonary fibrosis through synergistic therapeutic strategy
Binghua Wang, Yiwen Gao, Lulu sun, Meng Xue, Mingjin Wang, Zhenzhong Zhang, Lirong Zhang, Hongling Zhang
Biomaterials.2023; 303: 122404. CrossRef
|